Recently, the Clec9a targeted nanoemulsion vaccine formulation containing whole OVA protein antigen showed improved immunotherapy efficacy of CAR‐T cells that express transgenic T cell receptors (TCRs) specific to MHC class I or II restricted peptides.[55] Transgenic C57BL/6‐HER2 (human epidermal growth factor receptor 2) mice received the combined treatments completely regressed E0771‐Her2 breast cancer and MC38‐HER2 tumors. This evidence concerns the gene ERBB2 and breast cancer.